|
Tengion Inc., a clinical
stage regenerative medicine company focused on the development of
neo-organs and neo-tissues, announced that the results of a
preclinical research study conducted with its Tengion Neo-Bladder
Augment(TM) were published in the September issue of the Regenerative
Medicine, Vol. 3, Issue 5. The paper, “Long-term durability, tissue
regeneration and neo-organ growth during skeletal maturation with a
Neo-Bladder Augmentation Construct” was co-authored by Tengion scientists
Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., John W. Ludlow, Ph.D.,
Richard Payne, Ph.D., Belinda J. Wagner, Ph.D., and Timothy A. Bertram,
D.V.M., Ph.D. along with Gordon McLorie, MD from Wake Forest University
Baptist Medical Center. The article can be accessed via the website
http://www.futuremedicine.com/doi/abs/10.2217/17460751.3.5.671
The preclinical study, in which either a Neo-Bladder Augment or the
subject’s own native urinary bladder was surgically implanted following an
80% cystectomy and evaluated clinically at one, three, six, nine, 12, 18
and 24 months - showed that the Tengion Neo-Bladder Augment regained and
maintained native bladder histology by three months. The study also
demonstrated that the Neo-Bladder Augment regained baseline capacity at
three to six months and baseline compliance by 12-24 months. Importantly,
the Neo-Bladder Augment continued to adapt in size and function with
overall animal growth, or skeletal maturation.
“The results of this study are very encouraging for our overall
Neo-Bladder Augment program and, specifically, for our ongoing Neo-Bladder
Augment pediatric clinical trial. The children with spina bifida in that
trial are continuing to grow and mature and our goal is for the Neo-Bladder
Augment to demonstrate durability and the ability to adapt to
growth-related changes - as it has done in this pre-clinical model,” said
Dr. Bertram, Senior Vice President, Science and Technology of Tengion,
“Tengion is truly excited to continue to share positive research results
that help to further advance our neo-organ pipeline, and continue to
validate our Autologous Organ Regeneration Platform(TM).”
About Tengion
Tengion, a clinical stage biotechnology company, focuses on developing,
manufacturing and commercializing human neo-organs and neo-tissues using
our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible
materials and a patient’s own (autologous) cells to create a functional
neo-organ or neo-tissue that is designed to catalyze the body’s innate
ability to regenerate. Tengion’s product candidates may ultimately address
the most critical problems facing organ and tissue failure patients,
enabling people to lead healthier lives without donor transplants or the
side effects of related therapies.
Tengion Inc
http://www.tengion.com
Other news:
|
